Table 4.
Comparison of tumor growth inhibition after injection of different CPT formulations.
| Carriera | Cell strain (Source) | Days after first injection | Total dose (mg/kg) | Routesb | Tumor growth inhibitionc | Ref. |
|---|---|---|---|---|---|---|
| PEG-P(Asp(Bz-70)) | Colon 26 | 8 | 30 | Single | 18.5% | [35] |
| (Cell Resource Center, Tohoku University) | 8 | 15 | Single | 27.5% | ||
| 8 | 30 | 10 × 3 | 42.1% | |||
| HAS-DB-L | Colon 26 | 8 | 10 | Single | 34.6% | [37] |
| (Cell Resource Center, Tohoku University) | 8 | 20 | 10 × 2 | Mice dead | ||
| NPs-P/C1 | Colon-26 | 8 | 20 | 10 × 2 | 66.3% | [this work] |
| (CLS Cell Lines Service GmbH) | 12 | 30 | 10 × 3 | 49.5% |
a
PEG-P(Asp(Bz-70)): poly (ethylene glycol)-poly (benzyl aspartate-70); HAS-DB-L: PEG and human serum albumin coated 3,5-bis (dodecyloxy) benzoic acid; NPs-P/C1 : Pluronic F127/chitosan-functionalized camptothecin-loaded nanoparticles (weight of PLGA/weight of Pluronic F127 = 1:0.5).
b
All animals received intravenously injection via a lateral tail vein.
c
Tumor growth inhibition (T/C %) was calculated according to the following equation: T/C % = (mean tumor volume of treated group)/(mean tumor volume of control group).